Iteos Therapeutics (ITOS) investor relations material

Executive summary

• Announced wind-down of clinical and operational activities following termination of lead program and GSK collaboration; merger with Concentra Biosciences pending, with expected completion in Q3 2025.

• Lead antibody candidate belrestotug program discontinued after failing to meet key clinical endpoints; all related trials and collaboration with GSK ended.

• EOS-984 and EOS-215 programs remain as assets for potential disposition under the merger's contingent value rights (CVRs).

• Substantial doubt exists about ability to continue as a going concern absent completion of the merger or alternative transaction.

Financial highlights

• No revenue recognized in Q2 2025; $35.0M license and collaboration revenue recognized in Q2 2024 from GSK milestone.

• Net loss of $78.7M for Q2 2025, compared to $7.1M in Q2 2024; net loss of $113.3M for six months ended June 30, 2025, up from $45.3M year-over-year.

• Research and development expenses rose to $57.3M in Q2 2025 from $36.7M in Q2 2024, mainly due to GSK termination payment.

• Restructuring costs of $16.3M recorded in Q2 2025 related to severance and wind-down.

• Cash and cash equivalents of $207.8M and available-for-sale securities of $382.2M as of June 30, 2025.

Outlook and guidance

• Merger with Concentra expected to close in Q3 2025, subject to conditions including minimum $475M net cash at closing.

• If merger is not completed, company may pursue alternative strategic transaction or dissolution and liquidation.

• No plans to resume R&D if merger fails; wind-down of operations expected to be substantially complete in Q3 2025.